Bispecific Antibodies: New Therapies to Prolong Survival and Improve Quality of Life for Multiple Myeloma Patients Published on 02/09/2024 The incidence of bone marrow disease accounts for 10% of haematological malignancies.
The incorporation of monoclonal antibodies to first line treatment of Multiple Myeloma improves survival rates Published on 07/09/2021 Autologous transplantation continues to be part of the standard treatment for newly diagnosed patients with no comorbidities, as well as the combination of chemotherapy with the anti-CD38 monoclonal antibody